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Abstract: Increasing evidence points to an epigenetic contribution in Alzheimer’s disease (AD) pathogenesis. In 
this regard, variants and polymorphisms of DNA methyltransferase genes (DNMTs) are being investigated for their 
contribution to cognitive decline and dementia, but results are still scarce or controversial. In the present study we 
genotyped 710 Caucasian subjects of Italian descent, including 320 late-onset AD (LOAD) patients, 70 individuals 
with amnestic Mild Cognitive Impairment (MCI), and 320 matched healthy controls, for the presence of a functional 
DNMT3A -448A>G (rs1550117) polymorphism, searching for association with disease risk. In addition, we searched 
for correlation between the studied polymorphism and circulating levels of folate, homocysteine (hcy) and vitamin 
B12, all involved in DNA methylation reactions and available from 189 LOAD patients and 186 matched controls. 
Both allele and genotype frequencies of rs1550117 were closely similar between MCI, LOAD and control subjects, 
and no association with dementia or pre-dementia conditions was observed. Plasma hcy levels were significantly 
higher (p = 0.04) and serum folate levels significantly lower (p = 0.01) in LOAD than in controls, but no difference 
in circulating folate, hcy or vitamin B12 levels was seen between carriers and non-carriers of the minor DNMT3A 
-448A allele. Collectively, present results confirmed previous associations of increased hcy and decreased folate 
with LOAD risk, but do not support an association between the DNMT3A -448A>G polymorphism and AD in our 
population.
Keywords: DNMT3A -448A>G polymorphism, rs1550117, Alzheimer’s disease, Mild Cognitive Impairment, epi-
genetics, homocysteine, folate
Introduction
Alzheimer’s Disease is a neurodegenerative 
disorder representing the most common form 
of dementia in the elderly. The disease is char-
acterized by a progressive decline in cognitive 
functions resulting from the presence of extra-
cellular amyloid plaques and intracellular neu-
rofibrillary tangles, which ultimately lead to pre-
mature neuronal death [1, 2]. Only about 5% of 
AD cases present with an early-onset (EOAD) 
before the age of 65 years, whereas >95% of 
the patients develop the disease after the age 
of 65 years. They are classified as late-onset 
AD (LOAD) [3]. The disease is usually preceded 
by a pre-dementia phase referred as to amnes-
tic Mild Cognitive Impairment (aMCI), a condi-
tion that is considered to represent one of the 
earliest phases of the degenerative process 
leading to dementia of Alzheimer’s type [4]. 
LOAD is considered a multifactorial disease, 
resulting from a complex interplay between life-
long stochastic, genetic and environmental fac-
tors [5]. A growing body of evidence suggests 
an epigenetic contribution in LOAD, and global 
alterations of DNA methylation levels as well as 
gene-specific methylation changes have been 
reported in post-mortem AD brains or in blood 
DNA of living LOAD patients [6]. 
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DNA methylation consists in the addition of a 
methyl group to the C5 position of cytosine resi-
dues. Usually, it occurs on CpG dinucleotides in 
the promoter regions and represents a repres-
sive mark for gene expression [7]. DNA methyl-
ation reactions require S-adenosylmethionine 
(SAM) as the methyl donor compound. SAM is 
produced from the remethylation of homocys-
teine (hcy) to methionine in the one-carbon 
metabolic pathway, a complex biochemical 
pathway that requires dietary folates and vita-
min B12 as cofactors [8]. DNA methyltransfer-
ases (DNMTs) catalyze DNA methylation in a 
reaction that transfers the methyl group from 
SAM to the DNA, thus generating a methylated 
DNA template and S-adenosylhomocysteine 
(SAH), which is then converted back to hcy by 
SAH hydrolase. The DNMT family comprises 
several members, including the ‘maintenance’ 
methyltransferase DNMT1 that shows a prefer-
ence for hemimethylated DNA, and the ‘de 
novo’ methyltransferases DNMT3A and DNM- 
T3B [9].
Folates are B-group vitamins and the main 
nutritional determinants of plasma hcy levels. 
Epidemiological studies revealed that eleva-
tions in plasma hcy levels increase dementia 
risk and that there is an inverse correlation 
between plasma hcy concentrations and cogni-
tive performance in aged people [10, 11]. 
Indeed, AD patients often show decreased 
serum folate and vitamin B12 levels and 
increased homocysteinemia with respect to 
age-matched healthy subjects [12]. Studies on 
animal and cell models of AD showed that 
phisms were not associated with human intelli-
gence [17], neither with LOAD risk [18]. Asso- 
ciation studies aiming at investigating DNMT3B 
promoter polymorphisms and LOAD risk are 
controversial [19]. Besides these evidences, it 
is known that among the DNMTs, the DNMT3A 
appears to have a crucial role in neurogenesis, 
learning and memory as well as in age-related 
memory decline [20, 21]. In this regard, a 
DNMT3A -448 A>G promoter polymorphism 
(rs1550117) was recently proposed as a candi-
date LOAD risk factor in Chinese individuals 
[22]. 
We performed the present study in order to 
evaluate the contribution of rs1550117 to 
LOAD risk in Caucasian subjects of Italian ori-
gin. Furthermore, we compared allele and gen-
otype frequencies for rs1550117 between 
amnestic MCI subjects and healthy controls, 
and investigated the contribution of this poly-
morphism to circulating biomarkers of one-car-
bon metabolism (folate, hcy, and vitamin B12 
levels) available from 189 LOAD patients and 
186 healthy controls. 
Materials and methods
Subjects
DNA samples from a total of 320 LOAD patients, 
70 subjects with the diagnosis of aMCI, and 
320 non-demented healthy controls were col-
lected at the Department of Neuroscience of 
the Pisa University Hospital. Diagnosis of prob-
able AD was performed according to DSM-IV 
[23] and NINCDS-ADRDA criteria [24]. Based on 
Table 1. Demographic characteristics of the study population
Number Males (%) Females (%) Age (Mean ± SD)
AD 320 113 (35.3%) 207 (64.7%) 76.0 ± 7.3
MCI 70 30 (42.8%) 40 (57.2%) 74.0 ± 6.6
Controls 320 118 (36.9%) 202 (63.1%) 74.9 ± 8.7
B-vitamin deficiency results 
in hyperhomocysteinemia 
and impairment of DNA 
methyltransferase (DNMT) 
activities, leading to hypo-
methylation and increased 
expression of AD-related 
genes [13-15].
However, the contribution 
of DNMTs genes to LOAD 
is still controversial. Di 
Francesco and coworkers 
found an increase in global 
DNA methylation in LOAD 
blood DNA associated with 
higher DNMT1 expression 
and protein levels [16], but 
common DNMT1 polymor-
Table 2. Demographic characteristics of the subgroup with bio-
chemical data
AD (n = 189) Controls (n = 186) p-value
Age 77.6 ± 6.9 77.2 ± 9.8 0.73a
Gender (F/M) 121/68 112/74 0.46b
Homocysteine (μmol/l) 14.7 (11.33-21.8) 13.8 (10.6-17.8) 0.04c
Folate (ng/ml) 5.1 (3.8-7.3) 5.9 (4.6-8.2) 0.01c
Vitamin B12 (pg/ml) 364.0 (258.8-500.2) 387.5 (290-568.5) 0.16c
P-value obtained by means of at-test, bFisher’s exact test, cMann-Whitney U test.
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age at onset above 65 years and absence of a 
family history of dementia, all the subjects were 
regarded as sporadic LOAD cases. Cognitive 
dysfunction was measured in all patients using 
a battery of neuropsychological tests including 
the Auditory Verbal Learning Test (AVLT)-
delayed recall, the Mini-Mental State Exa- 
mination (MMSE), the Clinical Dementia Rating 
(CDR), and Activities of Daily Living (ADLs) 
Scale. All the 70 MCI individuals met the diag-
nostic criteria proposed by the Mayo Clinic 
Alzheimer’s Disease Research Centre for 
amnestic MCI [25]. Healthy volunteer subjects, 
matched with the patients for age and gender, 
were used as normal controls. Family history of 
dementia was ascertained by the Neurologists 
of the Department of Neuroscience of the Pisa 
University Hospital, excluding all the subjects 
with even one relative who developed AD or 
other dementias. All the control subjects were 
evaluated in order to exclude the presence of 
cognitive impairment. All the recruited individu-
als were Caucasians of Italian descent from at 
least three generations and the demographic 
characteristics of the case-control cohort are 
shown in Table 1. Each subject gave an 
informed and written consent for genotype 
analysis before blood drawing. The study was 
performed in accordance with the Declaration 
of Helsinki, following the requirements of the 
Ethics Committee of the Pisa University Hospital 
that approved the study (Protocol number 
3618/2012).
Genotyping 
Genomic DNA was isolated from whole blood by 
means of the QIAamp Blood Mini Kit (Qiagen, 
Milan, Italy) following the manufacturer’s 
instructions.
The DNMT3A -448A>G polymorphisms was 
determined by a PCR-RFLP assay adapted from 
[26]: a 175-bp product was amplified using 
1.25 units of Taq DNA polymerase (Euroclone, 
Milan, Italy), 5 pmol of the forward primer 
(5’-CTTGGGGCACCTCTGTCTAA-3’) and the re- 
verse primer (5’-AGTAGAATTCGGGGTGCAGA-3’), 
0.15 mM of each dNTP, 1.5 mM MgCl2, and 50 
ng of genomic DNA in a total volume of 25 µL. 
PCR conditions consisted of an initial denatur-
ation step of 5 minutes at 95°C, followed by 40 
cycles of 30 s at 95°C, 45 s at 59°C, and 45 s 
at 72°C and a final extension of 10 minutes at 
72°C. 
The PCR product was then digested with TaaI 
(Fermentas, Milan, Italy) for 2 h at 65°C; the 
digested products were separated on a 3.0% 
agarose gel and the RFLP bands visualized 
under ultraviolet light with ethidium bromide 
(EB) staining. The major G allele consists of a 
TaaI restriction site that results in two bands 
(132 bp and 43 bp, respectively), while the 
minor A allele is not digested resulting in an un-
cutted 175 bp fragment. Internal control sam-
ples, whose genotypes had been previously 
assessed, were always included and analyzed 
on each gel.
Biochemical analyses
Peripheral blood samples from 189 LOAD 
patients and 186 healthy controls have been 
collected during the neurological visit for the 
evaluation of circulating biomarkers of one-car-
bon metabolism. Those analyses were restrict-
ed to individuals not taking drugs or supple-
ments, such as B-vitamin supplements, known 
or suspected to interfere with one-carbon 
metabolism. Because of this we collected those 
Table 3. Distribution of genotype and allele frequencies in AD patients, MCI individuals and controls
Controls (%) AD (%) MCI (%)
ORa (95% CI) p-valuea ORa (95% CI) p-valuea ORa (95% CI) p-valuea
AD vs Controls MCI vs Controls AD + MCI vs Controls
Genotypes
    GG 260 (81.3%) 256 (80%) 57 (81.4%) 1.00b -- 1.00b -- 1.00b --
    GA 58 (18.1%) 60(18.8%) 13 (18.6%) 1.01 (0.67-1.54) 0.95 1.20 1.00 1.00 (0.68-1.49) 0.99
    AA 2 (0.6%) 4 (1.2%) 0 (0%) 1.18 (0.16-8.51) 0.87 -- -- 0.93 (0.13-6.68) 0.94
    AA+GA vs. GG 60 (18.7%) 64 (20%) 13 (18.6%) 1.02 (0.68-1.54) 0.92 1.19 1.00 1.00 (0.68-1.48) 0.99
    AA vs. GG+GA 2 (0.6%) 4 (1.2%) 0 (0%) 1.17 (0.16-8.4) 0.87 -- -- 0.92 (1.13-6.64) 0.94
Alleles
    Allele G 0.90 0.89 0.91 1.00b -- 1.00b -- 1.00b --
    Allele A 0.10 0.11 0.09 1.02 (0.69-1.49) 0.90 1.15 1.00 0.99 (0.69-1.43) 0.99
aAdjusted for age and gender. bReference values for OR. 
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data only from a subgroup of LOAD and control 
subjects that met the inclusion criteria, and 
have no data from aMCI individuals as most of 
them reported to take vitamin supplements. 
Table 2 shows the demographic characteristics 
of this subgroup. For what concerns the analy-
sis of circulating markers of one-carbon metab-
olism, the plasma was immediately separated 
and stored in freezer at -80°C. All the analyses 
were performed with standard protocols at the 
diagnostic laboratory of the Pisa University 
Hospital as detailed elsewhere [27]. Briefly: 
plasma hcy was measured by liquid chromatog-
raphy/tandem mass spectrometry. Serum 
folate and vitamin B12 were determined by 
electrochemiluminescence immunoassay ana- 
lyses. 
Statistical analyses
To verify that allele frequencies were in Hardy-
Weinberg equilibrium, and to assess differenc-
es in allele distributions between groups, we 
used the Chi-square (χ2) analysis. The differ-
ences in genotype frequencies were analyzed 
between the case and the control group by 2·2 
contingency tables using χ2 analysis or Fisher’s 
exact test. Odds ratios (ORs) have been calcu-
lated by means of logistic regression analysis 
and given with 95% confidence intervals (CIs). 
The power of the study was evaluated with the 
statistical package QUANTO 1.2.4.exe. Plasma 
hcy, serum folate and vitamin B12 values did 
not follow a normal distribution in our cohort, 
so that differences in median homocysteine, 
folate, and vitamin B12 levels between groups 
were assessed by means of the Mann-Whitney 
U test. The same test was used to correlate bio-
chemical data with the studied polymorphism. 
Statistical analyses were performed with the 
MedCalc v.12.5 and GraphPad Prism 6 soft-
ware. A p value <0.05 was considered as st- 
atistically significant.
Results
Genotyping 
Distribution of DNMT3A -448A>G allele and 
genotype frequencies in LOAD patients, MCI 
individuals, and healthy controls are shown in 
Table 3. The genotype frequencies conformed 
to Hardy-Weinberg expectations in controls (p = 
0.52). Both allele and genotype frequencies 
were similar between MCI, LOAD patients and 
controls, and no statistically significant differ-
ence was observed in the comparison of LOAD 
vs. controls, MCI vs. controls or LOAD+MCI vs. 
controls (Table 3).
Biochemical analyses
As shown in Table 2 we observed significantly 
increased median hcy levels (p = 0.04) and sig-
nificantly decreased median folate values (p = 
0.01) in LOAD patients with respect to controls. 
Vitamin B12 values were lower in the LOAD 
group than in controls, but this difference did 
not reach statistical significance (p = 0.16) 
(Table 2). 
Table 4. Comparison of Hcy, Folate and Vitamin B12 levels in total population (AD + Controls), AD 
patients and controls
Total AD Controls
Homocysteine (μmol/l)
    GG 13.9 (10.8-19.5) 15.0 (11.4-21.8) 13.3 (10.5-17.7)
    GA+AA 13.1 (10.7-19.9) 13.2 (11.3-21.3) 12.1 (10.2-19.1)
    p-valuea 0.69 0.69 0.99
Folate (ng/ml) 
    GG 5.3 (4.2-7.4) 5.0 (3.8-7.3) 5.7 (4.5-7.8)
    GA+AA 6.1 (4.1-8.5) 5.5 (3.8-7.0) 6.3 (4.0-8.5)
    p-valuea 0.39 0.64 0.81
Vitamin B12 (pg/ml)
    GG 370.0 (272.4-540.0) 357.8 (268.5-491.6) 401.0 (292.0-578.4)
    GA+AA 389.0 (241.0-538.0) 359.0 (224.5-550.0) 396.0 (305.6-499.0)
    p-valuea 0.62 0.93 0.47
aData are expressed as median (range) and the P-value is obtained by means of Mann-Whitney U test.
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Correlation between the DNMT3A -448A>G 
polymorphism and biochemical data 
We searched for a correlation between plasma 
hcy, and serum folate and vitamin B12 values 
with the DNMT3A -448A>G polymorphism. 
Given the very low frequency of homozygous AA 
carriers in our cohort (Table 3), comparisons 
were performed in A carriers (AA + GA) vs. non 
carriers (GG). As shown in Table 4 none of the 
studied biochemical markers of one-carbon 
metabolism (plasma hcy, serum folate or vita-
min B12) showed a different distribution 
between carriers and non-carriers of the 
DNMT3A -448A allele. 
Discussion
A very recent case-control study performed in 
Chinese LOAD patients reported association of 
the DNMT3A -448A>G polymorphism (rs15- 
50117) with disease risk [22]. Replication of 
those findings in populations other than Asians 
is required to better address the role of this 
polymorphism in LOAD, and we performed the 
present study to investigate the role of the 
DNMT3A -448A>G polymorphism in LOAD risk 
in a Caucasian cohort of Italian descent. For 
this purpose we genotyped 320 LOAD patients 
and 320 healthy controls matched for age and 
gender. We also addressed the contribution of 
the study polymorphism to circulating markers 
of one-carbon metabolism, namely plasma hcy 
and serum folate and vitamin B12 levels in 
LOAD and control subjects. Furthermore, we 
genotyped 70 aMCI subjects and compared 
allele and genotype frequencies of rs1550117 
in that cohort with those observed in healthy 
controls. The present study revealed very simi-
lar allele and genotype frequencies for 
rs1550117 between MCI, LOAD patients and 
controls and no association or trend for asso-
ciation with disease risk. Moreover, no differ-
ence in serum folate and vitamin B12 or in 
plasma hcy concentrations was seen between 
carriers and non-carriers of the minor A allele. 
Collectively, present data do not support a 
major role for the study polymorphism in AD 
risk in our population.
To date, different studies revealed a possible 
role of epigenetics and DNA methylation in AD 
[6]. In eukaryotes, DNA methylation consists of 
the addition of a methyl group from SAM to the 
C5 position of the cytosine residues in a reac-
tion catalyzed by DNMTs. DNMT1 is the mainte-
nance methyltransferase [28], shows a prefer-
ence for hemimethylated DNA [29, 30] and is 
ubiquitously and highly expressed in proliferat-
ing cells, representing the major DNMT activity 
in somatic tissues throughout mammalian 
development [31]. DNMT3A and DNMT3B are 
active de novo methyltransferases responsible 
for the establishment of DNA methylation pat-
terns during early development and in germ 
cells. There are several isoforms of both 
enzymes, which are differentially expressed at 
different stages of development and in differ-
ent tissues [32-34].
Studies on animal models showed that Dnmt1 
and Dnmt3a are expressed in post-mitotic neu-
rons and regulate neural plasticity [35, 36]. 
Particularly, two Dnmt3a isoforms (Dnmt3a1 
and Dnmt3a2) seem to be significantly reduced 
in brains of aged mice, likely contributing to 
age-related cognitive decline [20]. Similarly, it 
was suggested that DNMT3A moderates cogni-
tive decline in human subjects with MCI [37].
Several polymorphisms are known in DNMT 
genes and most of them have been associated 
with increased risk of human cancers [38, 39]. 
However, genetic association studies address-
ing the contribution of DNMT genes to 
Alzheimer’s disease or cognitive performances 
are still scarce and controversial [17-19, 37].
Among DNMT3A polymorphisms, the DNMT3A 
-448A>G one was associated with increased 
risk of cancer, particularly colorectal cancer, 
and a stratified analysis by ethnicity revealed 
significant increased cancer risk among Asians 
[39]. It was also demonstrated that the minor A 
allele increases the promoter activity (>2-fold) 
in in vitro studies [26]. Recently, Ling and col-
leagues investigated the DNMT3A -448A>G 
promoter polymorphism in 300 Chinese LOAD 
patients and 320 matched controls observing 
that this polymorphism was associated with a 
two-fold increased LOAD risk in their cohort 
[22]. Particularly, the A allele was more fre-
quent in Chinese LOAD patients (24%) than in 
healthy controls (20%), resulting in an 8% fre-
quency of DNMT3A -448 homozygous AA LOAD 
carriers [22]. Most of the available literature 
concerning the association of the study poly-
morphism with cancer risk was produced in 
Asian populations, showing minor allele fre-
quencies (MAF) for the DNMT3A -448A allele 
ranging from almost 20 to more than 30% and 
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association with cancer risk under various 
genetic models [39]. The present study showed 
that in our population the frequency of the 
minor A allele was significantly lower than in 
Asian cohorts and very similar in MCI, AD 
patients and healthy controls (about 10%, 
Table 3). Given a MAF of about 10% the present 
study had 85% statistical power to detect Odds 
Ratios (ORs) of 2.0 or higher for the minor allele. 
However, as shown in Table 3, both allele and 
genotype frequencies of rs1550117 were 
closely similar between MCI, LOAD and control 
subjects, no significant difference was ob- 
served, and none of the genetic models we 
addressed showed ORs similar to those report-
ed in Asians (Table 3). Particularly, the frequen-
cy of heterozygous AG subjects was highly simi-
lar among the three groups under investigation 
(Table 3), and that of homozygous AA subjects 
was lower than 1% in our cohort, being this gen-
otype detected only in 6 out of 710 genotyped 
subjects, and quite different from the 8% 
detected in Asian LOAD patients (Table 3). 
Collectively, present data do not support a 
major role for the study polymorphism in 
Caucasian LOAD patients of Italian descent. 
The allele and genotype frequencies of 
rs1550117 detected in the present study are 
consistent with those previously reported in the 
literature for European cohorts [40-42]. In this 
regard, previous studies in Caucasians of 
European descent investigated the role of 
DNMT3A -448A>G polymorphism in endome-
triosis, ovarian cancer and systemic lupus ery-
thematosus [40-42]. All these studies reported 
allele and genotype frequencies similar to 
those that we found in our population [40-42]. 
Furthermore, as confirmed by the International 
HapMap Project and the 1000 Genomes 
Project, this polymorphism is much more fre-
quent in Asians than Caucasians [43, 44].
We also addressed the contribution of the 
DNMT3A -448A>G polymorphism to circulating 
biomarkers of one-carbon metabolism. In liter-
ature there are several studies that evaluated 
one-carbon biomarker levels in LOAD patients 
and healthy controls, overall suggesting that 
increased plasma hcy levels and decreased 
serum folate levels could be regarded as LOAD 
risk factors [8, 45]. According to those data, our 
population showed a significant increase of hcy 
levels and a significant decrease of folate val-
ues in AD patients with respect to controls 
(Table 2). However, no difference in the circulat-
ing values of those biomarkers was seen 
between carriers and non-carriers of the 
DNMT3A -448A allele (Table 4). DNMTs trans-
fer the methyl group from SAM to the DNA in a 
reaction that generates SAH, which is then con-
verted to hcy by SAH hydrolase. Hcy can then 
re-enter the trans-methylation pathway being 
first re-methylated to methionine and then con-
verted to SAM. Hcy re-methylation requires 
folate derivatives as methyl donors and vitamin 
B12 as a cofactor [46]. It is therefore likely to 
hypothesize that functional DNMT3A polymor-
phisms could result in impaired hcy, folate or 
vitamin B12 levels, but no such effect was seen 
in the present cohort of LOAD and control sub-
jects, strengthening present results of lack of 
association between the DNMT3A -448A>G 
polymorphism and LOAD risk. 
Ethnic differences for variants in one-carbon 
metabolic genes and LOAD risk are known in 
the literature, and are likely to result from dif-
ferences in allele and genotype frequencies as 
well as from complex interactions among the 
studied polymorphisms and dietary or environ-
mental factors [46]. In this regard, the methy-
lenetetrahydrofolate reductase (MTHFR) 677C 
>T polymorphism represents one of the major 
determinants of circulating hcy levels and the 
most frequently studied polymorphism of the 
one-carbon metabolic pathway in LOAD genetic 
association studies [47]. However, a recent 
meta-analysis of 40 case-control studies 
revealed association of the MTHFR 677C>T 
polymorphism with LOAD risk in Asian popula-
tions, but not in Caucasians [47].
In conclusion, to the best of our knowledge the 
present is the first genetic association study 
addressing the contribution of rs1550117 to 
LOAD risk in Caucasians of Italian descent. We 
observed very similar allele and genotype distri-
butions of the study polymorphism among 
aMCI, LOAD and healthy matched controls and 
no association with dementia or pre-dementia 
conditions. Furthermore, no difference in circu-
lating markers of one-carbon metabolism was 
seen between carriers and non-carriers of the 
DNMT3A -448A>G minor allele. Collectively, 
present data do not support a major role for 
this polymorphism in AD risk among Caucasians 
of Italian descent. Additional studies in other 
LOAD groups are required to further address 
the contribution of this polymorphism to LOAD 
risk in different populations and ethnic groups.
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